Feasibility and outcome of repeat biopsy upon progression on tyrosine kinase inhibitors in patients with EGFR mutation positive adenocarcinoma of lung-an Indian tertiary cancer centre experience

被引：1
|
作者：
Zanwar, Saurabh
Noronha, Vanita
Joshi, Amit
Patil, Vijay Maruti
Chougule, Anuradha
Janu, Amit
Kumar, Rajiv
Prabhash, Kumar
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e20628
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20628
引用
收藏
页数：5
相关论文
共 50 条
  • [41] MET overexpression coexisting with epidermal growth factor receptor mutation influence clinical efficacy of EGFR-tyrosine kinase inhibitors in lung adenocarcinoma patients
    Ma, Lihong
    Song, Zhengbo
    Song, Yong
    Zhang, Yiping
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 (02) : 409 - 415
  • [42] EGFR mutation types and abundance were associated with the overall survival of advanced lung adenocarcinoma patients receiving first-line tyrosine kinase inhibitors
    Liu, Yang
    Wang, Hongyan
    Yang, Sen
    Yang, Yuanyuan
    Wu, Yufeng
    He, Zhen
    Ma, Shuxiang
    Mo, Yuqing
    Chen, Haiyang
    Wang, Qiming
    Ge, Hong
    JOURNAL OF THORACIC DISEASE, 2022, 14 (06) : 2254 - 2267
  • [43] RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation
    Yoshida, Tatsuya
    Yoh, Kiyotaka
    Niho, Seiji
    Umemura, Shigeki
    Matsumoto, Shingo
    Ohmatsu, Hironobu
    Ohe, Yuichiro
    Goto, Koichi
    LUNG CANCER, 2015, 90 (03) : 477 - 483
  • [44] A Progression Free Survival Score for EGFR Mutant Non-Small Cell Lung Cancer Patients Treat with First Line EGFR Tyrosine Kinase Inhibitors
    Chen, Yu-Mu
    Lin, Meng-Chih
    Fang, Wen-Feng
    Lie, Chien-Hao
    Chang, Huang-Chih
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S276 - S277
  • [45] Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer
    Rossi, Sabrina
    Finocchiaro, Giovanna
    Di Noia, Vincenzo
    Bonomi, Maria
    Cerchiaro, Eleonora
    De Rose, Fiorenza
    Franceschini, Davide
    Navarria, Pierina
    Ceresoli, Giovanni Luca
    Beretta, Giordano Domenico
    D'Argento, Ettore
    Scorsetti, Marta
    Santoro, Armando
    Toschi, Luca
    FUTURE ONCOLOGY, 2019, 15 (33) : 3775 - 3782
  • [46] Lung adenocarcinoma patient progression with gastrointestinal metastasis response to subsequent tyrosine kinase inhibitors (TKIs) from re-biopsy of new occurring driver gene mutation
    Zhou, Chunhua
    Yan, Binjie
    Zeng, Liang
    Xiong, Yi
    Liu, Li
    Yang, Nong
    Zhang, Yongchang
    JOURNAL OF THORACIC DISEASE, 2018, 10 (08) : E605 - E611
  • [47] Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in males, smokers, and non-adenocarcinoma lung cancer in patients with EGFR mutations
    Zeng, Zhu
    Chen, Hua-jun
    Yan, Hong-hong
    Yang, Jin-ji
    Zhang, Xu-chao
    Wu, Yi-long
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2013, 28 (03): : 249 - 258
  • [48] EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors
    Li, Chenguang
    Jia, Rui
    Liu, Hailin
    Zhang, Bin
    Wang, Changli
    DIAGNOSTIC PATHOLOGY, 2018, 13
  • [49] De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in EGFR Mutation-Positive Patients with Non-small Cell Lung Cancer
    Takeda, Masayuki
    Okamoto, Isamu
    Fujita, Yoshihiko
    Arao, Tokuzo
    Ito, Hiroyuki
    Fukuoka, Masahiro
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (03) : 399 - 400
  • [50] EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors
    Chenguang Li
    Rui Jia
    Hailin Liu
    Bin Zhang
    Changli Wang
    Diagnostic Pathology, 13
12345